BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 29, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2018

View Archived Issues

Separating graft attacks

Read More

BBB fails to slow down prions

Read More

Engineered oncolytic virus sticks with glioblastoma

Read More

Bayer initiates phase I II study of factor VIII gene transfer therapy with BAY-2599023

Read More

TRACON and I-Mab Biopharma enter immuno-oncology partnership

Read More

Identification of the PANK activator PZ-2891 for pantothenate kinase-associated neurodegeneration

Read More

Zogenix presents phase III data for fenfluramine in children and young adults with Dravet syndrome

Read More

First patient dosed in alloSHRINK phase I study of CYAD-101

Read More

Salivary RNA test developed for diagnosing childhood autism spectrum disorder

Read More

Bristol-Myers Squibb patents IRAK-4 inhibitors

Read More

Enanta Pharmaceuticals discloses MAP3K5 inhibitors

Read More

CD73 inhibitors reported in Eternity Bioscience patent

Read More

FDA clears IND application to initiate phase I/II study of KRAS G12C inhibitor, MRTX-849

Read More

ORIC Pharmaceuticals synthesizes CD73 inhibitors

Read More

Guangzhou Wellhealth Bio-Pharmaceutical divulges PARP-1 inhibitors

Read More

First subject successfully enrolled in first-in-human study of AT-1501 as treatment for ALS

Read More

Targeting the chromatin assembly factor complex blocks leukemia development in mice

Read More

Pain Therapeutics begins phase IIa study of PTI-125 in mild to moderate Alzheimer's disease

Read More

Bayer presents first phase I data for BAY-1093884 in patients with hemophilia

Read More

Leo Pharma initiates phase IIb studies of delgocitinib for atopic dermatitis and chronic hand eczema

Read More

ASH 2018: CRISPR screening gives clues to drug sensitivities of rare AML subtype

Read More

Biohaven reports topline data from phase III study of Zydis ODT rimegepant for acute migraine

Read More

Researchers present data for S-63845 in B-cell precursor ALL

Read More

Sienna reports phase IIb topline data on SNA-120 in psoriasis

Read More

Phase III ERADICATE Hp2 study of Talicia meets primary endpoint of H. pylori eradication

Read More

FDA approves Dextenza intracanalicular insert to treat postsurgical ocular pain

Read More

New phase II investigator-initiated study evaluates nitazoxanide in NASH-induced fibrosis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 28, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Three red darts on target

    Sun Pharma to acquire Merck spinoff Organon for $11.75B

    BioWorld
    Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing